API | varicella zoster virus glycoprotein e antigen

varicella zoster virus glycoprotein e antigen (Shingrix) Report issue

Vaccine Approved ^FDA

AACT

Active Ingredient History

NOW

A zoster vaccine is a vaccine that reduces the incidence of herpes zoster (shingles), a disease caused by reactivation of the varicella zoster virus (VZV), which is also responsible for chickenpox. Shingles provokes a painful rash with blisters, and can be followed by chronic pain, as well as other complications. Older people are more often affected, as are people with weakened immune systems (immunosuppression). Both shingles and postherpetic neuralgia can be prevented by vaccination. ^Wikipedia

Chemistry

SMILES: Missing data
InChIKey: Missing data
Mol. Mass: Missing data
ALogP: Missing data
ChEMBL Molecules: Missing data

More Chemistry

Pharmacology

Mechanisms of Action: Missing data
Multi-specific: Missing data
Black Box: Missing data
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: Missing data

hz/su vaccine | varicella zoster virus glycoprotein e antigen

Organizations (19)

Research & Development (19)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (1)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (21)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (21)

Allergy and Immunology (Early Phase 1)

Arthritis, Rheumatoid (Phase 4)

Chickenpox (Phase 2)

Colitis, Ulcerative (Phase 4)

Coronavirus Infections (Phase 1)

Crohn Disease (Phase 4)

Healthy Volunteers (Phase 4)

Herpes Zoster (Phase 4)

Herpes Zoster Vaccine (Phase 2)

Inflammatory Bowel Diseases (Phase 4)

Injection Site Reaction (Phase 4)

Kidney Transplantation (Phase 4)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Lung Diseases (Phase 2)

Lymphoma, Primary Cutaneous Anaplastic Large Cell (Phase 2)

Pain (Phase 4)

Pharmacological and Toxicological Phenomena (Phase 2)

Quality of Life (Phase 4)

Varicella Zoster Virus Infection (Phase 4)

Waldenstrom Macroglobulinemia (Phase 1)

Overview

Highest Phase: Phase 4
# of Trials: 18
# of Trial Organizations: 19

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue